Pharmacological characterization of the first in class clinical candidate PF‐05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose‐dependent insulin secretion ex vivo
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Ghrelin increases growth hormone secretion, gastric acid secretion, gastric motility and hunger but decreases glucose‐dependent insulin secretion and insulin sensitivity in humans. Antagonizing the ghrelin receptor has potential as a therapeutic approach in the treatment of obesity and type 2 diabetes. Therefore, the aim was to pharmacologically characterize the novel small‐molecule antagonist PF‐05190457 and assess translational pharmacology ex vivo. Experimental Approach: Radioligand binding in filter and scintillation proximity assay formats were used to evaluate affinity, and europium‐labelled GTP to assess functional activity. Rat vagal afferent firing and calcium imaging in dispersed islets were used as native tissues underlying food intake and insulin secretion respectively. Key Results: PF‐05190457 was a potent and selective inverse agonist on constitutively active ghrelin receptors and acted as a competitive antagonist of ghrelin action, with a human Kd of 3 nM requiring 4 h to achieve equilibrium. Potency of PF‐05190457 was similar across different species. PF‐05190457 increased intracellular calcium within dispersed islets and increased vagal afferent firing in a concentration‐dependent manner with similar potency but was threefold less potent as compared with the in vitro Ki in recombinant overexpressing cells. The effect of PF‐05190457 on rodent islets was comparable with glibenclamide, but glucose‐dependent and additive with the insulin secretagogue glucagon‐like peptide‐1. Conclusions and Implications: Together, these data provide the pharmacological in vitro and ex vivo characterization of the first ghrelin receptor inverse agonist, which has advanced into clinical trials to evaluate the therapeutic potential of blocking ghrelin receptors in obesity and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
Banks, W. A., Tschöp, M., Robinson, S. M., & Heiman, M. L. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034827 · Cited by 691 · cited 1×
“…effects of acylated ghrelin were originally considered to be acting on central ghrelin receptors as ghrelin crosses the blood brain barrier (Banks et al., 2002); however, it is now evident that many of ghrelin’s actions are mediated peripherally as the brain-impaired selective ghrelin…”
BackgroundHigh constitutive signaling of the ghrelin receptor–identification of a potent inverse agonist
Holst, B., Cygankiewicz, A., Jensen, T. H., Ankersen, M., & Schwartz, T. W. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0069 · Cited by 515
The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas
Wierup, N., Svensson, H., Mulder, H., & Sundler, F. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00067-8 · Cited by 457
Moens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250
Vestergaard, E. T., Gormsen, L. C., Jessen, N., Lund, S., Hansen, T. K., Moller, N., & Jorgensen, J. O. L. (2008) · Diabetes · doi:10.2337/db08-0025 · Cited by 156
Bhattacharya, S. K., Andrews, K., Beveridge, R., Cameron, K. O., Chen, C., Dunn, M., Fernando, D., Gao, H., Hepworth, D., Jackson, V. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400473x · Cited by 73 · cited 3×
“…while balancing absorption, distribution, metabolism, and excretion and off-target selectivity provided PF-05190457 (2-(2-methylimidazo[2,1-b][1,3]thiazol-6yl)-1-{2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1 H-inden1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethanone) (Bhattacharya et al., 2014).”
BackgroundMethodSelf-citation
Cited by
Ghrelin regulation of glucose metabolism
Poher, A.-L., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.015 · Cited by 186
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“PF-5190457 is a ghrelin receptor inverse agonist that inhibits GHS-R1a constitutive activity as well as blocking its activation by ghrelin [271].”
BackgroundLee, M. R., Tapocik, J. D., Ghareeb, M., Schwandt, M. L., Dias, A. A., Le, A. N., Cobbina, E., Farinelli, L. A., Bouhlal, S., Farokhnia, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0064-y · Cited by 129
Molecular mechanism of agonism and inverse agonism in ghrelin receptor
Qin, J., Cai, Y., Xu, Z., Ming, Q., Ji, S.-Y., Wu, C., Zhang, H., Mao, C., Shen, D.-D., Hirata, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-27975-9 · Cited by 57
Self-citation“Sibling” battle or harmony: Crosstalk between nesfatin-1 and ghrelin
Chen, X., Dong, J., Jiao, Q., Du, X., Bi, M., & Jiang, H. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04193-6 · Cited by 17
“Both ghrelin and GHSRs were detected in vagus nerve and ghrelin inhibited the mechanosensitivity of vagal afferent [207], while ghrelin receptor inverse agonist increased the firing rate of vagal afferent fibers [208].”
BackgroundInfluential
Metadata
- Authors
- Kong, J., Chuddy, J., Stock, I. A., Loria, P. M., Straub, S. V., Vage, C., Cameron, K. O., Bhattacharya, S. K., Lapham, K., McClure, K. F., Zhang, Y., & Jackson, V. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2016-03-17
- Volume
- 173
- Issue
- 9
- Pages
- 1452-1464
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2303915425
- Cited by
- 29
- References
- 7
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological characterization of the first in class clinical candidate PF‐05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose‐dependent insulin secretion ex vivo. https://app.cochat.ai/papers/10.1111/bph.13439
- The paper
- Kong, J., Chuddy, J., Stock, I. A., Loria, P. M., Straub, S. V., Vage, C., Cameron, K. O., Bhattacharya, S. K., Lapham, K., McClure, K. F., Zhang, Y., & Jackson, V. M. (2016). Pharmacological characterization of the first in class clinical candidate PF‐05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose‐dependent insulin secretion ex vivo. British Journal of Pharmacology. https://doi.org/10.1111/bph.13439
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.